200,275 research outputs found
PlanetScope images of Isabela (2018)
No full textPlanetScope multispectral images (3 m, Blue: 455 - 515 nm, Green: 500 - 590 nm, Red: 590 - 670 nm, Near-Infrared: 780 - 860 nm) of Isabela collected from 2018-03-04 to 2018-04-1
Isabela province (Philippines), bluff overlooking Cagayan River
No full textEchague--Angadanan, Isabela, Philippines. Northern Luzon. May 20, 1935. Bluff Cagayan River. Yearly cut 20 m in here! 0-20-30 Dk Br. - 10 m Br L Br. 8 1/25 G.GrayscalePendleton nitrate negative, Box 116 of 38
Quickbird images of Isabela highlands (2004)
No full textQuickbird panchromatic and multispectral images of the highlands of Isabela islands taken on 2004-10-22. Images have the following resolutions:
Spatial Resolution:
60 cm (24 in) (1.37 μrad) panchromatic at nadir
2.4 m (7 ft 10 in) (5.47 μrad) multispectral at nadir
Multispectral Channels:
blue (450–520 nm), green (520–600 nm), red (630–690 nm), near-IR (760–890 nm
Questionnaires and Information Sheets for Surveys WP1 and WP2
No full textSurvey for WP1 of Household Covid-19 UCC/ Ipsos Study
Survey for WP2 of Household Covid-19 UCC/ Ipsos Study
Survey information sheet for WP1 of Household Covid-19 UCC/ Ipsos Study
Survey information sheet for WP2 of Household Covid-19 UCC/ Ipsos Stud
On dragonfly nymphs (Insecta: Odonata: Anisoptera) from the caldera of the Cerro Azul volcano, Isla Isabela (Galápagos Archipelago, Ecuador).
No full textLambertz M, Spieth V, Denkinger J, Traunspurger W. On dragonfly nymphs (Insecta: Odonata: Anisoptera) from the caldera of the Cerro Azul volcano, Isla Isabela (Galápagos Archipelago, Ecuador). Bonn Zoological Bulletin. 2011;60(2):207-210
Quickbird images of coastline of Isabela and Fernandina (2005)
No full textQuickbird panchromatic and multispectral images of sections of the western coastline in Isabela and eastern coastline of Fernandina. Images have the following resolutions:
Spatial Resolution:
60 cm (24 in) (1.37 μrad) panchromatic at nadir
2.4 m (7 ft 10 in) (5.47 μrad) multispectral at nadir
Multispectral Channels:
blue (450–520 nm), green (520–600 nm), red (630–690 nm), near-IR (760–890 nm
Multiplicador analógico CMOS baseado na relação transcondutância X corrente
No full textDissertação (mestrado) - Universidade Federal de Santa Catarina, Centro Tecnológico. Programa de Pós-Graduação em Engenharia ElétricaO presente trabalho propõe um multiplicador operando em quarto quadrantes baseado em células que exploram a relação existente entre a corrente de saturação de um transistor MOS e a transcondutância de fonte. A vantagem da topologia proposta é simplicidade, operação com baixa potência, alta linearidade e corrente de saída com baixa sensibilidade dentro de uma mesma geração tecnológica. Os resultados de simulação associados aos experimentais demonstram a viabilidade da topologia escolhida para operação em baixa potência e baixa-tensão. A funcionalidade do sistema foi verificada através de simulação e da extração de parâmetros do protótipo implementado em tecnologia TSMC 0.35 m. Os resultados experimentais conseguidos com o protótipo indicam consumo de 1 mA, largura de banda de 1MHz e distorção harmônica total de 1% para uma corrente de entrada de 80 % do seu valor máximo sendo que a área de silício ocupada pelo multiplicador foi ao redor de 10.000 m2
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis:The ISABELA 1 and 2 Randomized Clinical Trials
No full textImportance: There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF). Objective: To assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with IPF. Design, Setting, and Participants: The 2 identically designed, phase 3, randomized clinical trials, ISABELA 1 and ISABELA 2, were conducted in Africa, Asia-Pacific region, Europe, Latin America, the Middle East, and North America (26 countries). A total of 1306 patients with IPF were randomized (525 patients at 106 sites in ISABELA 1 and 781 patients at 121 sites in ISABELA 2). Enrollment began in November 2018 in both trials and follow-up was completed early due to study termination on April 12, 2021, for ISABELA 1 and on March 30, 2021, for ISABELA 2. Interventions: Patients were randomized 1:1:1 to receive 600 mg of oral ziritaxestat, 200 mg of ziritaxestat, or placebo once daily in addition to local standard of care (pirfenidone, nintedanib, or neither) for at least 52 weeks. Main Outcomes and Measures: The primary outcome was the annual rate of decline for forced vital capacity (FVC) at week 52. The key secondary outcomes were disease progression, time to first respiratory-related hospitalization, and change from baseline in St George's Respiratory Questionnaire total score (range, 0 to 100; higher scores indicate poorer health-related quality of life). Results: At the time of study termination, 525 patients were randomized in ISABELA 1 and 781 patients in ISABELA 2 (mean age: 70.0 [SD, 7.2] years in ISABELA 1 and 69.8 [SD, 7.1] years in ISABELA 2; male: 82.4% and 81.2%, respectively). The trials were terminated early after an independent data and safety monitoring committee concluded that the benefit to risk profile of ziritaxestat no longer supported their continuation. Ziritaxestat did not improve the annual rate of FVC decline vs placebo in either study. In ISABELA 1, the least-squares mean annual rate of FVC decline was -124.6 mL (95% CI, -178.0 to -71.2 mL) with 600 mg of ziritaxestat vs -147.3 mL (95% CI, -199.8 to -94.7 mL) with placebo (between-group difference, 22.7 mL [95% CI, -52.3 to 97.6 mL]), and -173.9 mL (95% CI, -225.7 to -122.2 mL) with 200 mg of ziritaxestat (between-group difference vs placebo, -26.7 mL [95% CI, -100.5 to 47.1 mL]). In ISABELA 2, the least-squares mean annual rate of FVC decline was -173.8 mL (95% CI, -209.2 to -138.4 mL) with 600 mg of ziritaxestat vs -176.6 mL (95% CI, -211.4 to -141.8 mL) with placebo (between-group difference, 2.8 mL [95% CI, -46.9 to 52.4 mL]) and -174.9 mL (95% CI, -209.5 to -140.2 mL) with 200 mg of ziritaxestat (between-group difference vs placebo, 1.7 mL [95% CI, -47.4 to 50.8 mL]). There was no benefit with ziritaxestat vs placebo for the key secondary outcomes. In ISABELA 1, all-cause mortality was 8.0% with 600 mg of ziritaxestat, 4.6% with 200 mg of ziritaxestat, and 6.3% with placebo; in ISABELA 2, it was 9.3% with 600 mg of ziritaxestat, 8.5% with 200 mg of ziritaxestat, and 4.7% with placebo. Conclusions and Relevance: Ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF receiving standard of care treatment with pirfenidone or nintedanib or in those not receiving standard of care treatment. Trial Registration: ClinicalTrials.gov Identifiers: NCT03711162 and NCT03733444.</p
International course on water and water management in the Philippines 2013
No full textSince 2011, the Faculty of Social Sciences (FSW) and the Institute of Environmental Sciences (CML) of Leiden University, in cooperation with Isabela State University and the Mabuwaya Foundation in the Philippines organize an annual month–long international, interdisciplinary field course on sustainable development, water issues and water management in the Cagayan River basin and Sierra Madre Mountains in Northeast Luzon in the Philippines. Thirty students usually participate in this course, 15 through Leiden University and 15 through Isabela State University. The students are enrolled in different studies, encompassing social, natural and applied sciences. The annual report contains background information about that year’s course, all student reports and the online blog that the students maintained during the course.Environmental BiologyConservation Biolog
Dr. Duane M. Jackson, Morehouse College, July 2011
No full textThis video is a conversation with Dr. Duane M. Jackson. Dr. Jackson talks about his paper, "Recall and the Serial Position Effect: The Role of Primacy and Recency on Accounting Students' Performance." Jackie Daniel, AUC Woodruff Library, is the interviewer
- …
